| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA1126: natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy |
|
Medicine details |
|
| Medicine name | natalizumab (Tyruko® & Tysabri®) |
| Formulation | 300 mg concentrate for solution for infusion |
| Reference number | 8080 & 5199 |
| Indication | Single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups: • Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or • Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain Magnetic Resonance Imaging (MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI. |
| Company | Sandoz Ltd (Tyruko®), Biogen Idec Ltd (Tysabri®) |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/12/2025 |
| NICE guidance | |